Innate Pharma (IPHA) Total Debt (2017 - 2025)

Innate Pharma (IPHA) has disclosed Total Debt for 8 consecutive years, with $33.1 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Total Debt fell 22.84% year-over-year to $33.1 million, compared with a TTM value of $33.1 million through Dec 2024, down 22.84%, and an annual FY2024 reading of $33.5 million, down 22.26% over the prior year.
  • Total Debt was $33.1 million for Q4 2024 at Innate Pharma, down from $42.9 million in the prior quarter.
  • Across five years, Total Debt topped out at $50.6 million in Q4 2021 and bottomed at $22.8 million in Q4 2020.
  • Average Total Debt over 5 years is $38.5 million, with a median of $42.9 million recorded in 2023.
  • The sharpest move saw Total Debt surged 122.44% in 2021, then dropped 22.84% in 2024.
  • Year by year, Total Debt stood at $22.8 million in 2020, then soared by 122.44% to $50.6 million in 2021, then fell by 14.85% to $43.1 million in 2022, then decreased by 0.43% to $42.9 million in 2023, then decreased by 22.84% to $33.1 million in 2024.
  • Business Quant data shows Total Debt for IPHA at $33.1 million in Q4 2024, $42.9 million in Q4 2023, and $43.1 million in Q4 2022.